Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Devices specialist bids farewell to Commission:

This article was originally published in Clinica

Executive Summary

The European Commission is about to lose one of its most experienced members of staff in the medical devices field. Karen Howes, who initially joined the medical devices unit as a technical expert on attachment to the Commission from the UK's MDA in 1996, will be leaving at the end of April when her contract expires. Ms Howes has some five years of experience at the Commission having returned to the MDA in December 1999 when her then three-year contract expired only to welcomed back to the Commission in November 2000 on a new two-and-a-half year contract, no longer on attachment to the MDA. Ms Howes told Clinica that she intends to remain in the medical devices sector and hopes to work in industry "after a little sabbatical". Ms Howes' replacement has not yet been named.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel